ALA: CT lung screening has 'lifesaving' potential

In its annual report on lung cancer in the U.S., the American Lung Association...Read more on AuntMinnie.comRelated Reading: CT lung screening proves cost-effective even at older ages Life expectancy model refines CT lung screening criteria ISCT: 10 pillars of an effective CT lung screening program Demographic factors limit access to CT lung screening Patient outreach may boost uptake for CT lung screening
Source: Headlines - Category: Radiology Source Type: news

Related Links:

Publication date: Available online 30 March 2020Source: Journal of EthnopharmacologyAuthor(s): Zu-Jun Que, Bin Luo, Chen-Tong Wang, Fang-Fang Qian, Yi Jiang, Yan Li, Xiang-Hui Han, He-Gen Li, Jia-Xiang Liu, Jian-Hui Tian
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
This study evaluated the distribution of the crizotinib patient information brochure (PIB) in Europe and patient knowledge of the key messages in the PIB. A cross‐sectional survey was conducted in 10 European countries among pa tients who received crizotinib to ascertain whether each patient received and read the PIB, and his/her knowledge of its key messages on hepatotoxicity, interstitial lung disease/pneumonitis, QTc prolongation, bradycardia, and vision disorders. Of the 341 patients contacted, 40 responded (11.7%), an d 39 patients were eligible. A total of 77% of respondents acknowledged receiving the PIB, of which...
Source: Pharmacology Research and Perspectives - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionThe results of this study showed that there are some differences in term of protein content between the normal and cancerous lung tissues. Further studies are needed to evaluate these proteins that investigate whether these proteins can candidate as biomarkers to use in the early diagnosis of patients with NSCLC.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Publication date: July 2020Source: Materials Science and Engineering: C, Volume 112Author(s): Jun Tang, Fushuang Zheng, Jungang Zhao, Jianzhu Zhao
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Source: Journal of Coordination Chemistry - Category: Chemistry Authors: Source Type: research
Researchers determined that artificial intelligence could help predict responses to systemic therapies for patients with non-small cell lung cancer by utilizing CT scans.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
AbstractBackgroundSubxiphoid uniportal video ‐assisted thoracoscopic surgery (SVATS) is more technically challenging than intercostal uniportal video‐assisted thoracoscopic surgery (UVATS), especially in more complex procedures such as segmentectomy. We therefore aimed to investigate the worthiness of undertaking the more demanding subxiph oid approach in patients who had undergone anatomical segmentectomy for stage IA non‐small cell lung cancer (NSCLC).MethodsA total of 491 patients were included in our study who had undergone anatomical segmentectomy for stage IA non ‐small cell lung cancer from September 2014 to...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Cardiovascular disease is an important contributor to particle ‐induced diseases. Inhalation of (nano)particles induces acute phase response, a known risk factor for cardiovascular disease. New evidence is reviewed, showing causal relationships between inhalation of particle and nanomaterials, induction of acute phase response and risk of cardiovascular disea se. Particle‐induced acute phase response provides a means for risk assessment of particle‐induced cardiovascular disease. AbstractInhaled nanoparticles constitute a potential health hazard due to their size ‐dependent lung deposition and large surface to mass...
Source: Small - Category: Nanotechnology Authors: Tags: Review Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
30 March 2020 -- AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC)...
Source: - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Radiology